31651-76-0

Basic information

• Product Name: DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER
• Synonyms: DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER;Dichloridophosphoric acid 1-naphtyl ester;Dichlorophosphinic acid 1-naphtyl ester;Phosphorodichloridic acid 1-naphtyl ester
• CAS NO: 31651-76-0
• Molecular Formula: C₁₀H₇Cl₂O₂P
• Molecular Weight: 261.04
• Mol File: 31651-76-0.mol

Chemical Properties

• Boiling Point: 199-201 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.466±0.06 g/cm3(Predicted)
• CAS DataBase Reference: DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER(31651-76-0)
• EPA Substance Registry System: DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER(31651-76-0)

Safety Data

• Hazardous Substances Data: 31651-76-0(Hazardous Substances Data)

Usage

Uses

Used in Pesticide Production:
DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER is used as a chemical intermediate for the production of phosphorus-containing pesticides. It plays a critical role in the synthesis of these agricultural chemicals, which are designed to protect crops from pests and ensure a stable food supply.
Used in Flame Retardant Manufacturing:
DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER is also utilized as an intermediate in the creation of flame retardants. Flame retardants are essential in various industries to prevent the ignition and spread of fires, thereby enhancing safety and reducing property damage.
Used in Plasticizer Production:
DICHLOROPHOSPHONIC ACID-[1]NAPHTHYL ESTER serves as a key intermediate in the manufacturing of plasticizers, which are additives used to increase the flexibility, workability, and durability of various plastic materials. These plasticizers are employed across a wide range of applications, from consumer products to industrial components.

Upstream product

• 90-15-3 α-naphthol 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 1136-89-6 1-naphthylphosphoric acid 
• 96413-68-2 1-naphthyl bis(p-nitrophenyl) phosphate 
• 691411-31-1 (1R,3S,5S)-2,4-Dibenzyl-1,8,8-trimethyl-3-(naphthalen-1-yloxy)-2,4-diaza-3-phospha-bicyclo[3.2.1]octane 3-oxide 
• 874362-22-8 1-naphthyl-(methoxy-L-phenylalaninyl)phosphochloridate 
• 874362-14-8 1-naphthyl-(benzoxy-dimethylglycinyl)-phosphorochloridate 
• 874362-20-6 (S)-2-[chloro-(naphthalen-1-yloxy)-phosphorylamino]-3-methyl butyric acid benzyl ester 
• 874362-24-0 naphthalene-1-yl-L-phenylalanine benzyloxy ester phosphorochloridate 
• 874362-17-1 1-naphthyl-(methoxy-L-phenylglycinyl)phosphochloridate 
• 874362-26-2 1-naphthyl-(benzoxy-D-alaninyl)phosphochloridate 
• 874362-16-0 1-naphthyl-(benzoxy-L-isoleucinyl)phosphochloridate 

Relevant articles and documents

Structural Effects in Phosphates. 1. Comparison of 4-Nitrophenyl 1-Naphthyl and 4-Nitrophenyl Quinolin-8-yl Phosphates

Crystal and molecular structures of quinolin-8-yl bis(p-nitrophenyl) (4), quinolin-8-yl p-nitrophenyl (4a), and 1-naphthyl bis(p-nitrophenyl) phosphates (5) have been determined and compared.In 4 the donor-acceptor nitrogen-phosphorus interactions change the geometry of the molecule from tetrahedral to quasi-tbp, so the structure can be considered as an "early stage" of the intramolecular displacement of the PNPO group.In 4a this interaction is replaced by intramolecular N:H:O hydrogen bonding.The intramolecular nonbonded potential energies of 4 and 5 were calculated, and the minimum-energy conformations obtained were compared with those determined by X-ray diffraction.The results of calculations confirm the observed differences in the intramolecular interactions operating in 4 and 5.The mass spectra of 4 and 5 reveal a dramatic difference between these two phosphates with respect to the fragmentation involving the expulsion of the p-nitrophenoxy radical and the formation of the corresponding phosphorylium ion by the nitrogen atom.Rate measurements for the base-catalyzed hydrolysis of the P-OPNP linkage show that 4 is not significantly more reactive than 5 and provide no evidence for the intramolecular nucleophilic catalysis in the hydrolysis of 4.

Naphthyl phosphoramidate derivatives of BVdU as potential anticancer agents: Design, synthesis and biological evaluation

The phosphoramidate technology we have developed has been recently applied to BVdU, leading to NB1011 (NewBiotics Inc., California), a novel potential anticancer compound recently entered into phase 2 of the clinical trials for colon cancer. We report in

Prodrug compound and application ofprodrug compound in treatment of cancer

The present invention provides a compound indicated by a formula (I), pharmaceutically acceptable salts or esters thereof, a pharmaceutical composition of the compound, and application of the compoundand the pharmaceutical composition in the inhibition or regulation of the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

Deuterated compound and application thereof in treatment of cancer

The present invention relates to a deuterated compound and application thereof in the treatment of cancer. Specifically, the present invention provides the compound of formula (I) and pharmaceuticallyacceptable salt or ester thereof, and a pharmaceutical composition thereof. The compound and the pharmaceutical composition are used for inhibiting or regulating the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER

There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)

PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS

There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. (I)

Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs

Unmasked phohate groups of phosphotyrosine-containing molecules carry two negative charges at physiological pH, which compromise their (passive) cellular uptake. Also, these phosphate groups are often cleaved off by phosphatases. Together, these ultimatel

4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION

Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV

PHOSPHORODIAMIDATES AND OTHER PHOSPHORUS DERIVATIVES OF FINGOLIMOD AND RELATED S1 P RECEPTOR MODULATORS

Compounds of general formula (I): (Formula I)) wherein R1, Q, R3, R4, R5, R6, R7 and Ar1 are as defined herein are inhibitors of class I histone deacetylases and are of use in th

FLOXURIDINE SYNTHESIS

The present invention relates to a process for the preparation of floxuridine, said process comprising reacting a compound of Formula la with a compound of Formula lla in the presence of an acid Al to provide a compound of Formula Ilia in substantially diastereomerically pure form. Floxuridine may be useful as an anti-cancer drug. Floxuridine may also be useful in the preparation of other anti-cancer drugs, e.g. NUC-3373.